Active surveillance for favorable-risk prostate cancer: Who, how and why?

Nature Clinical Practice Oncology

Volumn 4, Issue 12, 2007, Pages 692-698

  Klotz, Laurence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; AGE DISTRIBUTION; CANCER GROWTH; CANCER RISK; CANCER SCREENING; CLINICAL FEATURE; COMORBIDITY; HISTOPATHOLOGY; HUMAN; PATIENT CODING; PATIENT IDENTIFICATION; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; REVIEW; RISK ASSESSMENT;

ADAPTATION, PSYCHOLOGICAL; AGED; ALGORITHMS; DISEASE PROGRESSION; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 36549016713     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0966     Document Type: Review

References (32)

1. Nadler RB et al. (2005) Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol 174: 2154-2157
2. Welch HG et al. (2005) Prostate-specific antigen levels in the United States: Implications of various definitions for abnormal. J Natl Cancer Inst 97: 1132-1137
3. Jemal A et al. (2007) Cancer Statistics, 2007. CA Cancer J Clin 57: 43-66
4. D'Arrico AV et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Insur Med 30: 204-205
5. Sakr WA et al. (1993) The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150: 379
6. Albertsen P et al. (2005) 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 2095-2101
7. Albertsen PC et al. (2005) Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97:1248-1253
8. Stamey TA et al. (1993) Localized prostate cancer: Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71 (Suppl): S933-S938
9. Epstein JI et al. (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1 c) prostate cancer. JAMA 271: 368-374
10. Epstein JI et al. (1993) Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71 3582-3593
11. Irwin MB and Trapasso JG (1994) Identification of insignificant prostate cancers: Analysis of preoperative parameters. Urology 44: 862-867
12. Cupp MR et al. (1995) The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 153 1543-1548
13. Goto Y et al. (1996) Distinguishing clinically important from unimportant prostate cancers before treatment: Value of systematic biopsies. J Urol 156: 1059-1063
14. Epstein JI et al. (1993) Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol 149: 1478-1481
15. Epstein JI et al. (1998) Nonpalpable stage T1 c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160: 2407-2411
16. Noguchi M et al. (2001) Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: Lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 166: 104-109
17. Augustin H et al. (2003) Insignificant prostate cancer in radical prostatectomy specimen: Time trends and preoperative prediction. Eur Urol 43: 455-460
18. Anast JW et al. (2004) Relating biopsy and clinical variables to radical prostatectomy findings: Can insignificant and advanced prostate cancer be predicted in a screening population? Urology 64: 544-550
19. Graif T et al. (2007) Under diagnosis and over diagnosis of prostate cancer. J Urol 178: 88-92
20. Thompson IM et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215-224
21. Choo R et al. (2001) PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 50: 615-620
22. Roemeling S et al. (2007) Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 51 1244-1250
23. Kakehi Y (2003) PSA DT in Japanese active surveillance cohort (48 patients). Jpn J Clin Oncol 33: 1-5
24. Teahan SJ and Klotz LH (2006) Current role of prostate-specific antigen kinetics in managing patients with prostate cancer. BJU Int 97 451-455
25. Egawa S et al. (2000) Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 3: 269-274
26. McLaren DB et al. (1998) Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 82: 342-348
27. D'Amico AV et al. (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351: 125-135
28. Choo R et al. (2002) Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167: 1664-1669
29. Klotz L (2005) Active surveillance for prostate cancer: For whom? J Clin Oncol 23: 8165-8169
30. Bill-Axelson A et al. (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352: 1977-1984
31. Khan MA et al. (2003) Expectant management of localized prostate cancer. Urology 62: 793-799
32. Steineck G et al. (2002) Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 347: 790-796